| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
PSNGR1 is smart travel management made simple. Sign up your company to leverage preferred content, corporate controls and our proprietary marketplace to connect with preferred suppliers.
Imaginea is a Mountain View, CA-based company in the Software and Internet sector.
Acorn selects the strategically relevant influencers focused on creating and delivering authentic content to your target audience at the right place and the right time.
A fully integrated Cloud Based Property Management System